Pipeline
Our DARPin platform has vast applicability across a range of diseases. Explore our pipeline:
Oncology
Discovery Oncology
Virology
Ophthalmology
Candidate
Research
Preclinical
Phase 1
Phase 2
Phase 3
Rights
Virology
Research


Immune Cell Engagers
Research


- The Company continues to evaluate potential business opportunities for abicipar, outside of Molecular Partners.
- Molecular Partners was informed by Novartis that the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep was withdrawn effective January 25th, 2023. As previously disclosed, ensovibep is not presently in clinical development.